Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory B Cell Malignancies

NCT04011293 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT04011293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04011293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory B Cell Malignancies
Lead sponsor
Shandong University
Phase
Phase 1
Overall status
Unknown status
Start date
July 31, 2019
Completion date
April 30, 2022
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory hematological malignancies